March 24, 2026 – (Investorides.com Newswire) Breaking Reports for Medical Tech Stock News, a leading investment platform for retail investors
Athlon Medical, Inc.
(Nasdaq: AEMD), a medical therapeutics company focused on developing products to treat cancer and life-threatening infectious diseases.
Athlon Medical, Inc.
(Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Athlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of participant data from the second cohort and is ready to proceed to the third and final cohort. Is recommended. They also stated that “no safety concerns were noted with the hemopurifier device/procedure”.
A trial titled “Safety, feasibility, and dose-finding study of the Athlon Hemopurifier in patients with solid tumors who have stable or progressive disease during treatment with pembrolizumab or nivolumab” is being conducted to assess the safety, feasibility, and optimal dosing of the hemopurifier.
The DSMB – which included independent medical experts in nephrology and oncology – reviewed data from participants enrolled in the second group, in which patients received two hemopurifier treatments over a one-week period. Based on their assessment, the DSMB found no safety concerns and confirmed that the hemopurifier continues to demonstrate a favorable safety and tolerability profile. To date, no serious adverse events (SAEs) or dose-limiting toxicities (DLTs) related to the Hemopurifier device or treatment have been reported.
“The continued positive recommendation from the DSMB supports the safety profile observed to date and allows us to move forward into the third and final cohort of this study,” said Steven LaRosa, MD, chief medical officer of Athlon Medical. “We are encouraged by the increasing pace of the trial and the final data set and clinical study report to share with potential investors, partners and regulatory agencies.”
Nomination for Group 3 is now open. In this final group, participants will receive three hemopurifier treatments over a one-week period, with safety, feasibility and dosing parameters evaluated at the study’s three active clinical sites in Australia. The trial is designed to enroll approximately 9 to 18 patients with solid tumors who have stable or progressive disease while receiving treatment that includes pembrolizumab (Keytruda®) or nivolumab (Opdivo®).
The primary endpoint of this trial is the incidence of adverse events and clinically significant changes in safety laboratory tests of hemopurifier-treated patients. In addition to safety monitoring, the study is designed to investigate the number of hemopurifier treatments required to reduce the concentration of extracellular vesicles (EVs) and whether these changes in EV concentrations improve the body’s own natural ability to attack tumor cells. These findings are expected to inform the design of future efficacy and safety premarket approval (PMA) studies required by regulatory authorities.
Athlon Medical, Inc. is committed to advancing the hemopurifier for use in oncology and will continue to provide updates as clinical trials proceed.
Athlon Medical, Inc. About this
Athlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Athlon is advancing the hemopurifier to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulating pathogen targets from biological fluids.
For more information visit
www.AethlonMedical.com
And follow the company on LinkedIn.
About Athlon and Hemopurifier®
Athlon Medical is a medical therapeutics company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, Hemopurifier has demonstrated removal of life-threatening viruses and in pre-clinical studies, Hemopurifier has demonstrated removal of harmful EVs from biological fluids using its proprietary lectin-based technology. This action has potential applications in cancer, where EVs can promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a US Food and Drug Administration (FDA) designated breakthrough device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant to standard of care therapy, and across cancer types in which EVs have been shown to participate in disease progression or severity. The HemoPurifier also has an FDA Breakthrough Device Designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed by approved therapies.
Further information can be found here
www.AethlonMedical.com.
forward-looking statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as “may,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “will,” “estimate,” “estimate,” “potential” or similar words constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from those anticipated in the forward-looking statements. Risks and uncertainties include, but are not limited to, clinical trial results, regulatory approvals, ability to obtain additional financing and market acceptance of the Company’s products, as more fully described in the Company’s filings with the Securities and Exchange Commission. These forward-looking statements are based on Athlon’s current expectations and contain assumptions that may never be realized or may prove incorrect. All forward-looking statements included in this press release speak only as of the date on which they are made. Except as required by law, the Company does not intend and undertake no duty to update this information to reflect future events or circumstances.
Company Contact:
gym freaks
Chief Executive Officer and Chief Financial Officer
Athlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
susan nunan
SA Noonan Communications, LLC
susan@sanoonan.com
Athlon Medical Inc. (NASDAQ:AEMD) is a featured biotech stock on Investorideas.com. See more information about AEMD on Investorideas.com:
https://www.investorideas.com/CO/AEMD/
Receive news alerts on Athlon Medical
get more Biotech and Medical Tech News, ArticlesPodcast and stock directories
About Investorideas.com – Big Investment Ideas
Investorideas.com is the go-to platform for great investment ideas. From breaking stock news to top-rated investing podcasts, we cover it all
Follow us
Follow us on Facebook
https://www.facebook.com/Investorideas
Follow us on You Tube
https://www.youtube.com/c/Investorideas
Sign up for free stock news alerts at Investorideas.com
https://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/Disclosure: Athelon Medical, Inc. (AEMD) is a paid feature medical technology Stocks on Investor Ideas More Disclosure: Investorideas.com is a digital publisher of news, articles and equity research sourced from third parties as well as creating original content including videos, interviews and articles. Original content created by Investidea is protected by copyright laws in addition to syndication rights. Our site does not make recommendations for the purchase or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investments involve risk and possible loss. The site currently offers compensation for news publishing and distribution, social media and marketing, content creation, and more. Further Disclosures: Contact each company’s management and IR directly regarding specific questions.
